Today is an important day for Zeltia shareholders since the drug Yondelis ®, developed by the division PharmaMar biotechnology has been adopted by the European Medicines Agency to be used in the treatment of a specific cancer, soft tissue sarcoma. However, this substance, trabectidina is also being investigated to check their possible use in other more common cancers like breast or ovarian cancer, so it is possible that many patients can actually benefit from this new drug the future. This antitumor has been developed within a broader research project of substances of therapeutic interest in the sea, an interesting project and risky from the point of view. Specifically, the active substance that has given rise to this new drug was originally isolated from a marine tunicate : Ecteinascidia turbinata and is an important example of the search for new drugs as before, may lie in methodological research of natural substances. Do not forget, relatively speaking, this is the case of two of the most commonly used drugs: aspirin or aspirin was discovered following an investigation of substances of white willow bark and eventually led to the chemist Felix Hoffmann at Bayer the synthesis of this important analgesic marketed in 1899. On the other hand we owe to the fungus and bacteriologist Fleming's discovery of penicillin in 1928, but finally it was the participation of the chemical pathologist Chain and Florey which enabled her utilización.Hoy day the advance of techniques X-ray diffraction and nanotechnology provide insight into the three-dimensional structure of many proteins could be target of new drugs and computer design is another important alternative for the pharmaceutical industry, although we will always have the sea.
0 comments:
Post a Comment